HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. - Wülfing,P.; Borchard,J.; Buerger,H.; Heidl,S.; Zanker,K.S.; Kiesel,L.; Brandt,B. (Clin Cancer Res, 2006)